货号:A246079
同义名:
亚叶酸钙五水合物
/ Leucovorin Calcium Pentahydrate; Leucovorin calcium salt pentahydrate
Folinic acid calcium salt pentahydrate 是一种还原型叶酸,常与甲氨蝶呤联合使用,作为化疗药物的辅助剂,降低其毒性并提高疗效。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | DHFR ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pralatrexate | ✔ | 99%+ | |||||||||||||||||
| Pemetrexed disodium |
++++
DHFR, Ki: 7.2 nM |
99% | |||||||||||||||||
| Pyrimethamine |
++
DHFR, IC50: 15.4 nM |
98% HPLC | |||||||||||||||||
| Pemetrexed |
++++
DHFR , Ki: 7.2 nM |
99+% | |||||||||||||||||
| Methotrexate |
+
hDHFR, IC50: 24 nM |
99% (contain ~10%water) | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | The biologically active form of folic acid is tetrahydrofolate which is essential for DNA synthesis. Tetrahydrofolate is oxidised to dihydrofolate during DNA synthesis and is regenerated to its active form by the enzyme dihydrofolate reductase. Inhibition of this enzyme prevents DNA synthesis and causes failure of cell renewal. This leads to breaks in epithelial surfaces resulting in oropharyngeal and intestinal ulceration. Methotrexate (MTX) is the most powerful antagonist to inhibit dihydrofolate reductase. Folinic acid is an analogue of tetrahydrofolate and so bypasses the dihydrofolate reductase block. It thus supplies the tetrahydrofolate compounds needed for DNA synthesis [3]. Treatment with folinic acid calcium pentahydrate (CF) could cause improved development in the heart and vessels in MTX-treated embryos, which proved that MTX induced the malformations by inhibiting dihydrofolate reductase (DHFR). The transcript levels of genes such as hand2, mef2a, mef2c, and flk-1 were reduced in MTX-treated embryos. Compared with the MTX-treated group, the transcript levels of hand2, mef2a, mef2c, and flk-1 were increased in the MTX + CF group [4]. Folinic Acid Calcium Pentahydrate may also be useful in the treatment of acute methotrexate overdose [3]. |
| Concentration | Treated Time | Description | References | |
| Human aortic endothelial cells (HAEC) | 10 μM | 1 hour | To evaluate the effect of BH4 treatment on intracellular BH4 and 7,8-BH2 levels. Results showed a transient increase in intracellular BH4 followed by accumulation of 7,8-BH2. | Free Radic Biol Med. 2013 Oct;63:143-50. |
| Human umbilical vein endothelial cells (HUVEC) | 500 nM | 24 h | Folinic acid reversed MTX-induced p38 MAPK and Akt phosphorylation and reduced MTX-induced pro-inflammatory cell adhesion molecules (VCAM1, ICAM1, and E-selectin) expression. | Front Immunol. 2023 Jun 30;14:1209490. |
| MCA38 colorectal cancer cell line | 10 μM | 48 h | To evaluate the effect of FOLFOX (including folinic acid) on MCA38 cells, confirming cell death and activation of inflammatory signaling. | Br J Cancer. 2013 Oct 29;109(9):2396-403. |
| Administration | Dosage | Frequency | Description | References | ||
| BALB/c mice | Acute Toxoplasma gondii RH strain infection model | Oral administration | 15 mg/kg | Once daily for 7 consecutive days | As a positive control drug to evaluate the therapeutic effect of folinic acid on acute Toxoplasma gondii infection | Parasit Vectors. 2024 Mar 1;17(1):96 |
| BALB/c mice | Acute Toxoplasma gondii infection model | Oral administration | 15 mg/kg | Once daily for 15 consecutive days | Evaluated the therapeutic effect of folinic acid on acute infection, results showed all mice in the positive control drug groups survived | Front Cell Dev Biol. 2021 Jun 11;9:684393 |
| BALB/c mice | Toxoplasma gondii infection model | Oral | 15 mg/kg | Once a day for 30 days | Evaluate the safety of folinic acid in Toxoplasma gondii infection model | Front Microbiol. 2019 Sep 18;10:2152 |
| BALB/c mice | Acute T. gondii infection model | Oral administration | 15 mg/kg | Once daily for 7 consecutive days | To evaluate the therapeutic effect of folinic acid on acute T. gondii infection, all mice in the positive drug groups survived. | Int J Parasitol Drugs Drug Resist. 2019 Apr;9:27-34 |
| C57Bl/6 mice | Colorectal liver metastases (CRLM) model | Intraperitoneal (i.p.) | 90 mg kg | Weekly cycles, terminated one day after the third treatment | To evaluate the effect of FOLFOX (including folinic acid) on the CRLM model, finding that tumour-related factors exacerbated FOLFOX-induced liver injury. | Br J Cancer. 2013 Oct 29;109(9):2396-403. |
| Dose | Mice: 7 mg/kg[3] (i.p.) |
| Administration | i.p. |
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00720109 | Adult B Acute Lymphoblastic Le... 展开 >>ukemia With t(9;22)(q34;q11.2); BCR-ABL1 Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 Untreated Adult Acute Lymphoblastic Leukemia Untreated Childhood Acute Lymphoblastic Leukemia 收起 << | Phase 2 Phase 3 | Completed | - | - |
| NCT01256398 | Acute Lymphoblastic Leukemia ... 展开 >> Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 Untreated Adult Acute Lymphoblastic Leukemia 收起 << | Phase 2 | Active, not recruiting | - | - |
| NCT00720109 | - | Completed | - | - | |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.66mL 0.33mL 0.17mL |
8.31mL 1.66mL 0.83mL |
16.62mL 3.32mL 1.66mL |
|
| CAS号 | 6035-45-6 |
| 分子式 | C20H31CaN7O12 |
| 分子量 | 601.58 |
| SMILES Code | O=CN1C(C2=O)=C(NC(N)=N2)NCC1CNC3=CC=C(C(N[C@H](C([O-])=O)CCC([O-])=O)=O)C=C3.O.O.O.O.[Ca+2].O |
| MDL No. | MFCD00149465 |
| 别名 | 亚叶酸钙五水合物 ;Leucovorin Calcium Pentahydrate; Leucovorin calcium salt pentahydrate |
| 运输 | 蓝冰 |
| InChI Key | NPPBLUASYYNAIG-ZIGBGYJWSA-L |
| Pubchem ID | 135802074 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, 2-8°C |
| 溶解方案 |
H2O: 10 mg/mL(16.62 mM),配合低频超声助溶 |
沪公网安备 31011702889066号
沪ICP备2024050318号-1